UK Markets close in 20 mins

Ambu A/S (AMBU-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
97.84+2.84 (+2.99%)
At close: 04:59PM CET
Full screen
Previous close95.00
Open95.00
Bid97.68 x 0
Ask97.84 x 0
Day's range94.22 - 97.84
52-week range61.26 - 184.70
Volume1,121,100
Avg. volume1,353,766
Market cap24.825B
Beta (5Y monthly)0.55
PE ratio (TTM)83.91
EPS (TTM)1.17
Earnings date23 Jan 2023 - 27 Jan 2023
Forward dividend & yield0.29 (0.34%)
Ex-dividend date15 Dec 2021
1y target est96.75
  • Globe Newswire

    Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities

    Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S. The attached document discloses the data of the transactions made in Ambu shares. Attachment 29_11_2022 Thomas F Schmidt

  • Globe Newswire

    Annual Report 2021/22

    Today, Ambu issues the Annual Report for the financial year 2021/22, including Sustainability Report and Remuneration Report. The reports can be found at Ambu.com. Attachments Remuneration Report 2021-22 - Ambu Sustainability Report 2021-2022 - Ambu Ambu-2022-09-30-en Annual Report 2021-22 - Ambu

  • Globe Newswire

    ANNUAL RESULTS 2021/22 (EARNINGS RELEASE)

    Ambu delivered 4% organic revenue growth for the year 2021/22. Global Endoscopy Solutions (previously named Visualisation) revenues grew organically by 1%, mainly driven by strong growth in the ENT (Ear-Nose-Throat) and urology segments, offset by declining sales in the pulmonology segment, mostly due to high Covid-19 comparables. The Anaesthesia and Patient Monitoring businesses posted positive organic growth of 5% and 13%, respectively, driven by pent-up demand and recovery from the Covid-19 p